Medications that activate multiple related hormone receptors lower blood pressure more than those activating only one receptor in adults with overweight or obesity, with measurable differences in...

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.

Systematic Review With Meta-Analysis

Human

2026 May 15

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Effect of Incretin-Based Therapies on Blood Pressure: A Systematic Review and Meta-Analysis.

Score: 47

DOI: 10.1093/eurjpc/zwaf560

Similar Assertions

Medications called incretin-based therapies, such as GLP-1 receptor agonists, lower systolic blood pressure by about 3.4 mmHg and diastolic blood pressure by about 0.9 mmHg in adults who have overweight or obesity.

80%

GLP-1 drugs are changing the game for treating obesity because they help people lose more weight and improve heart and metabolic health better than older treatments.

73%